RGRicardo Grieshaber-Bouyer

Ricardo Grieshaber-Bouyer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ricardo Grieshaber-Bouyer has a total of 298 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CD19-CAR T cells reset the EBV + autoreactive B cell repertoire in autoimmune disease

    by Ya’EL Courtney, Mahesh Pandit, Laura S. van Dam, Shady Younis, Sajede Rasouli, Mengrui Zhang, Yashaar Chaichian, Shima Parsafar, Tobias V. Lanz, Eline J. Arends, et al.

    Epstein-Barr virus (EBV) reprograms autoreactive B cells into activated antigen-presenting cells that drive pathogenic T- and B-cell responses in autoimmune disease. 1–4 Whether eliminating these cells contributes to durable remission after CD19 chimeric antigen receptor (CAR) T-cell therapy 5–7 is unknown. Here, using EBV B-cell sequencing (EBV-seq) 3 , we profiled EBV + B cells from patients treated with CD19-CAR T cells (systemic lupus erythematosus, n=6; inflammatory myopathy, n=3; systemic sclerosis, n=3) or rituximab (n=15) and recombinantly expressed their antibodies to define antigen specificity. At baseline, EBV + B cells were enriched relative to healthy donors, class-switched and hypermutated, expressed the latency III program with heightened antigen-presentation signatures, and encoded autoantibodies. CAR T cells, but not rituximab, depleted EBV + B cells and shifted the reconstituted repertoire towards IgM + , minimally mutated, largely non-autoreactive cells, consistent with infection of newly generated B cells. After rituximab, EBV + B cells retained a class-switched, hypermutated and autoreactive with an activated antigen-presenting phenotype. Sustained drug-free remission occurred in 8/12 CAR T-cell-treated versus 0/15 rituximab-treated patients. In vitro , EBV + B cells resisted anti-CD20 and anti-CD19 antibodies but were killed by CAR T cells and a CD19 T-cell engager. Our findings suggest resetting the EBV + autoreactive B-cell repertoire contributes to sustained drug-free remission.

  • Rescue therapy of paediatric lupus nephritis with plasma cell-directed antibodies

    by Sivakanthan Kasinathan, Imelda M. Balboni, Joyce Hsu, Paul C. Grimm, Jack Yeung, Shaun W. Jackson, William H. Robinson, Amanda Moyer, Alice Bertaina, Jessie L. Alexander, et al.

  • Use of advanced therapies in systemic lupus erythematosus: a retrospective single-centre analysis based on disease phenotypes

    by Elaine Degen, Chiu Wai Shirley Chan, Koray Tascilar, Fabian Hartmann, Georg Schett, Panagiotis Garantziotis, Ricardo Grieshaber-Bouyer

    Objectives: To identify and analyse distinct subgroups of SLE based on serological and demographic profiles, and to assess their impact on clinical manifestations, disease activity and use of advanced therapies. Methods: We performed a cross-sectional analysis of a single-centre cohort of 327 SLE patients. Hierarchical cluster analysis was used to identify groups based on 10 serological features: anti-dsDNA, anti-Sm, lupus anti-coagulant, anti-cardiolipin, anti-B2GP1, hypocomplementemia, direct Coombs test, anti-Ro, anti-La and anti-RNP. We further stratified patients by age of onset and sex. Results: The cohort was predominantly female (84.7%). Four serological clusters emerged: Cluster 1 (anti-Sm/RNP), Cluster 2 (aPL), Cluster 3 (anti-Ro/La) and Cluster 4 (dsDNA positive and ENA/aPL scarce). Cluster 1 (anti-Sm/RNP) was associated with the most severe phenotype, with higher rates of serositis (P = 0.001) and cutaneous manifestations (P = 0.006). These patients required multiple immunosuppressants (P = 0.01) and had the highest utilization of biologics (P = 0.024). Conversely, Cluster 4 showed the lowest disease activity (P = 0.004) and highest rates of DORIS remission (P = 0.004). Notably, patients with late-onset SLE received significantly fewer biologics (11.1% vs 35.5%, P < 0.001) and conventional immunosuppressants (68.5% vs 83.2%, P = 0.013), yet they accrued greater cumulative organ damage (SDI >0: 70.4% vs 52.4%, P = 0.015) compared with early-onset patients. Conclusion: The anti-Sm/RNP signature identifies a severe, refractory phenotype, potentially necessitating intensified biologic therapy. Late-onset SLE represents a silent risk group, where lower treatment intensity correlates with higher damage accrual, suggesting current management strategies may be insufficient. These findings challenge the standard of care and support the implementation of serology-guided stratification.

  • Open Access

    Rheumatologists’ expectations and perceptions of T-cell redirecting therapies: results from a cross-sectional survey

    by Anna Meinecke, Johannes Knitza, Thorben Witte, Judith Rademacher, Felix Müller, Christina Düsing, Marco Zeeck, Ricardo Grieshaber-Bouyer, Melanie Hagen, Isabell Haase, et al.

    T-cell redirecting therapies (TCRTs), including Chimeric antigen receptor (CAR)-T cells and T-cell engagers (TCEs), are emerging as transformative treatments for autoimmune diseases. However, clinical application is currently restricted to specialized centers, leaving most clinicians with limited first-hand experience. We aimed to assess the knowledge, perception, and barriers regarding TCRTs among German rheumatologists. A prospective, web-based survey was distributed to German rheumatologists via congresses and digital channels from September 2024 through January 2025. Drafting the design and reporting of the survey results was performed regarding international recommendations as the “checklist for reporting results of internet e-surveys” (CHERRIES). Statistical analysis was conducted with SPSS. Of 98 participants (median age 43 years) the majority was based at university hospitals (46.3%) and 94.8% were willing to refer patients to specialized centers. However, respondents considered only 5% of their patients suitable for TCRT, primarily those with severe, refractory connective tissue diseases. The main barriers cited were high costs (82%), limited clinical experience (65.5%) and applicability in only a limited number of patients (35.4%). Knowledge of side effects (e.g., cytokine release syndrome, infections, hypogammaglobulinemia) and contraindications (e.g. heart failure, chronic infections) was generally accurate. Yet, the self-appraisal of existing knowledge on TCRT was only seen as medium by the questioned rheumatologists (median of 4.86, on a 0 to 10 scale with 10 is best knowledge). Participating German rheumatologists demonstrated a high willingness to refer patients for TCRTs and appeared to possess good safety knowledge. However, the therapy is currently viewed as a niche option for highly active, refractory cases, with costs and limited data serving as primary barriers to broader implementation.

  • Open Access

    Low-dose blinatumomab in multidrug-resistant rheumatoid arthritis—a case series

    by Laura Bucci, Melanie Hagen, Sebastian Böltz, Carlo Tur, Danae-Mona Nöthling, Tobias Dashi, Janina Auth, Tobias Rothe, Andreas Wirsching, Jochen Wacker, et al.


  • Open Access

    A Feed-Forward Loop Between Extrafollicular B Cell Differentiation and the Inflammatory Milieu Governs Remission and Relapse in Systemic Lupus Erythematosus

    by Danae-Mona Nöthling, Kirill Anoshkin, Patrick G. Gavin, Tobias Rothe, Laura Bucci, Futoshi Iwata, Panagiotis Garantziotis, Nicola Ferrari, Sarah L.N. Clarke, Melanie Hagen, et al.

    Systemic lupus erythematosus (SLE) is driven by pathogenic B cells. Yet, why some patients receiving B cell depletion achieve durable remission, whilst others fail remains unclear. Here we use CD19-directed chimeric antigen receptor (CAR) T cell therapy as a mechanistic probe in 18 patients with refractory SLE 1,2 , with longitudinal follow-up extending up to 40 months. We show that durable, drug-free remission is defined not by the depth of B cell depletion alone, but by the elimination of the extrafollicular (EF) B cell differentiation trajectory – specifically, activated naïve B cell precursors and CD11c + T-bet + double-negative type 2 B cells. In long-term responders, B cell reconstitution recapitulated healthy ontogeny, while the EF pathway remained truncated, coinciding with collapse of the interferon-rich milieu and contraction of PD1 hi T peripheral helper cells. In contrast, in relapse, persistently elevated CXCL13, interferons and expanded PD1 hi T cells preceded the B cell return, and nascent B cells immediately followed the EF differentiation trajectory in the confirmed absence of germinal centers in the lymph node, shortly followed by clinical symptoms. These findings indicate that CAR-T cell therapy achieves remission by breaking a feed-forward loop between the systemic inflammatory environment and extrafollicular B cell differentiation.

  • Open Access

    The cell cloud: Adopting systems biology concepts in the era of single-cell immunology

    by Tal Shay, Christophe O. Benoist, Ricardo Grieshaber-Bouyer

    High-throughput single-cell assays reveal data that defies discrete categorization. The ‘cell cloud’ model, grounded in established systems biology principles, offers a framework to navigate biological plasticity alongside technical variability.

  • T cell engagers in autoimmune diseases

    by Ricardo Grieshaber-Bouyer, Lei Wu, Georg Schett, Patrick A. Baeuerle

    T cell engagers (TCEs) are antibody-based, bispecific or multi-specific constructs that can reprogramme T cells to eliminate target cells expressing a defined surface antigen. Originally developed for cancer therapy, TCEs are now being investigated for the treatment of autoimmune diseases, with promising initial results. The interest in using TCEs for autoimmune diseases is rapidly growing given their comparable potency with cellular therapies, combined with the advantages of biologics, including ease of manufacturing, off-the-shelf availability, better safety and more convenient delivery. Here we review the history of TCEs, focus on distinct aspects of the mechanism of action of TCEs and explain design principles. We also discuss key challenges for future TCE development in autoimmunity, including enhanced safety, high convenience and complete target cell elimination. Finally, we provide an overview of the preclinical and clinical development landscape and give an outlook on next-generation TCEs that are optimized to treat a wide variety of autoimmune diseases.


  • Open Access

    Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells

    by Aleix Rius Rigau, Meilin Xu, Ziyuan Liu, Sara Chenguiti Fakhouri, Janina Auth, Panagiotis Garantziotis, Andrea Zoli, Manoj Kumar Selvaraju, Maria Gabriella Raimondo, Carlo Tur, et al.

    Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy and fibrotic remodeling of the skin and internal organs. Fibrotic tissue changes are considered hardly reversible with current therapies, suggesting that new strategies are required to modulate the disease-associated molecular and cellular phenotype to enable regeneration of affected tissues. Here, analyzing skin biopsy samples from patients with SSc who had received CD19-CAR T cell therapy as part of the CASTLE study or named patient use, we demonstrate structural regeneration of SSc skin structure, as evidenced by recovery of skin papillae. Consistent with these histological changes, cyclic in situ hybridization and imaging mass cytometry analyses suggested that fibroblast populations shifted towards a physiological state, both in terms of composition and function. Moreover, we describe signs of vascular repair and changes in epidermal cell function. These results suggest that B cell depletion using CD19-CAR T cell therapy may lead to skin tissue remodeling in SSc and highlight its potential for tissue regeneration in fibrotic diseases.


  • T-cell engagers mediate deep cell depletion beyond autoimmunity

    by Johanna T. Kurzhagen, William Laqua, Mario Schiffer, Ricardo Grieshaber-Bouyer